Joint Formulary & PAD

Eltrombopag - Immune thrombocytopenia

You are here : Home > Formulary Search > Eltrombopag - Immune thrombocytopenia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
ICB
NICE
SPC
Restrictions / Comments :

Documentation

Guidelines (Local)
USE OF THROMBOPOETIN RECEPTOR AGONISTS (TPO RAs) AND FOSTAMATINIB IN THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN ADULTS October 2024.pdf
NICE Technology Appraisal
NICE TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura

PAD Profile

ChemicalSubstance :
Eltrombopag
Indication :
Immune thrombocytopenia
Group Name :
Keywords :
ITP, chronic immune thrombocytopenia, idiopathic thrombocytopenic purpura
Brand Names Include :
Revolade
Important Information :

Haematology use only - treating chronic immune thrombocytopenia as per NICE TA293.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Immune thrombocytopenia
Supporting Documents :
2

Committee Recommendations (2)

04 Sep 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves the updated ITP pathway.

03 Jun 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

ITP treatment pathway has been updated to include sequential use of eltrombopag & romiplostim

Other Indications

Below are listed other indications that Eltrombopag is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Immune thrombocytopenia.